Qing Dong

Conforma Therapeutics Corp. designs and develops drugs for treatment of cancer. It also develops applications in the areas of medicine, including inflammation, virology and central nervous system disorders. The company was founded in 1999 and is headquartered in Cambridge, MA.

Cabrellis Pharmaceuticals Corp. manufactures medical products. The firm develops therapies for treatment of cancer. The company was founded by Thomas M. Estok, Lawrence C. Fritz and Christopher C. LeMasters in 2006 and is headquartered in Summit, NJ.

Adimab LLC provides human therapeutic antibodies. The firm has discovered antibodies for a wide variety of therapeutic targets within many disease areas, including oncology, immunomodulation, inflammation, neuroscience and pain, cardiovascular and metabolic disease and infectious disease. The company was founded in 2007 by Tillman Gerngross, Dane Wittrup and Errik Anderson and is headquartered in Lebanon, NH.

Compass Therapeutics LLC operates as a healthcare industry focusing on biotechnology. It offers drug discovery, development, biologics, oncology and immuno-oncology. The company was founded by Errik B. Anderson and Thomas J. Schuetz in 2014 and is headquartered in Cambridge, MA.

Prospect Venture Partners (Prospect Venture Partners) is a venture capital firm founded in 1997 by Alexander E. Barkas and David Schnell. The firm is headquartered in Palo Alto, California.

Foresite Capital Management LLC (Foresite Capital) is a private equity firm founded in 2010 by James Tananbaum. The firm is headquartered in San Francisco.

Seragon Pharmaceuticals, Inc. developes biopharmaceutical products for the treatment of estrogen receptor dependent breast cancer. The company was founded in 2013 and is headquartered in San Diego, CA.

Balance Therapeutics, Inc. develops therapeutics to address conditions of intellectual disability. Its pharmacological approach, based on technology licensed from Stanford University, hypothesizes that restoring the proper balance between inhibition and excitation at the neuronal synapse by antagonizing excessive inhibitory circuits could result in the appropriate plasticity for memory and learning to occur in many conditions of intellectual disability. The company was founded by Lyndon Lien, Craig Garner and Daniel Wetmore in 2009 and is headquartered in San Bruno, CA.

Adicet Therapeutics, Inc. operates as a biopharmaceutical company focuses on the development of cell immunotherapies. It engages in the design and development of immunotherapies for cancer and other disease indications with a focus on novel universal immune cell therapies. The company was founded by Aya Jakobovits in 2014 and is headquartered in Beverly Hills, CA.

Gemini Therapeutics Sub, Inc. engages in the development of treatments for age-related macular degeneration (AMD) and linked ocular disorders. Its multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies. The company was founded by James McLaughlin, Johanna Seddon, Paul Barlow and Andrew Herbert in 2015 and is headquartered in Cambridge, MA.

Fount Therapeutics LLC operates a drug discovery enterprise. The company was founded by Eric Murphy and Steve W. Kaldor and is headquartered in San Marcos, CA.

Maze Therapeutics, Inc. is a is a biopharmaceutical company, which engages in the development of portfolio of therapeutic candidates for a number of genetically defined diseases. It focuses on translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, cutting-edge functional genomics, and an array of drug discovery approaches. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman in 2018 and is headquartered in San Francisco, CA.

Emendo Biotherapeutics, Inc. engages in the development of genome editing technology. It specializes in protein engineering, molecular biology, and gene editing systems. The company was founded by David Baram, Lior Izhar, and Rachel Diamant in 2015 and is headquartered in New York, NY.

Kumquat Biosciences, Inc. provides biotechnology services. The company was founded by Yi Liu and Pingda Ren and is headquartered in San Diego, CA.

Odyssey Therapeutics, Inc. is a biotechnology company that specializes in discovering, developing, and commercializing immunomodulators and oncology medicines. The company is based in Medfield, MA and has subsidiaries in the United Kingdom. The company is composed of a team of drug hunters, scientists, and industry leaders in foundational biology, chemistry, and data sciences. Odyssey Therapeutics aims to transform drug discovery to accelerate and drive the creation and efficient delivery of life-enhancing precision medicines to patients. Odyssey Therapeutics was founded by David L. Pompliano, Gary D. Glick, and Melissa Merrick, with Gary D. Glick serving as the CEO since incorporation.

Blossomhill Therapeutics, Inc. is a small molecule drug discovery and development company that focuses on unmet medical needs in oncology and autoimmune disorders. The company is based in San Diego, CA. Dr. Cui is the lead inventor of multiple oncology medicines and clinical compounds, including crizotinib, lorlatinib, repotrectinib (TPX-0005), TPX-0022, TPX-0046, and TPX-0131. The company was founded by J. Jean Cui, Ph.D., a renowned drug design and development scientist, and Y. Peter Li, Ph.D., M.B.A., a biotech veteran. Jing Rong Cui has been the CEO since incorporation.

Alumis, Inc. manufactures and sells pharmaceutical products for neuroinflammatory, neurodegenerative, and immune diseases. The company is based in San Francisco, CA. The company was founded by June H Lee. Martin Babler has been the CEO of the company since 2021.

Gwynant Therapeutics develops new small molecules for oncology targets.

Garuda Therapeutics, Inc. aims to eliminate the need for donor or patient cells for blood stem cell transplants. The company is based in Natick, MA. The company's platform technology generates off-the-shelf, self-renewing blood stem cells that are HLA-compatible and transgene-free. This technology could potentially provide curative therapies for over 120 diseases. Garuda Therapeutics was founded by Dhvanit Shah, Sean Morrison, and David T. Scadden, with Dhvanit Shah serving as CEO since incorporation.

True North Therapeutics, Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, and commercialization of first-in-class product candidates for complement-mediated diseases. The company was founded by Nancy E. Stagliano in 2013 and is headquartered in South San Francisco, CA.